-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer

被引:28
作者
Han, Zhenfu [1 ]
Harris, Peter K. W. [1 ]
Karmakar, Partha [1 ]
Kim, Tommy [1 ]
Owusu, Ben Y. [2 ]
Wildman, Scott A. [1 ,3 ]
Klampfer, Lidija [2 ]
Janetka, James W. [1 ]
机构
[1] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, Dept Biochem & Mol Biophys, 660 S Euclid Ave, St Louis, MO 63110 USA
[2] So Res Inst, Dept Oncol, 2000 9th Ave, Birmingham, AL 35205 USA
[3] Univ Wisconsin, Carbone Canc Ctr, Sch Med & Publ Hlth, Madison, WI 53792 USA
关键词
cancer; cell signaling; metastasis; serine protease inhibitors; solid-phase peptide synthesis; structure-based drug design; HEPATOCYTE GROWTH-FACTOR; MACROPHAGE-STIMULATING PROTEIN; BREAST-CANCER; SELECTIVE INHIBITORS; FACTOR ACTIVATOR; CELL-LINES; C-MET; PROGNOSTIC-SIGNIFICANCE; MATRIPTASE INHIBITORS; ONCOGENE ADDICTION;
D O I
10.1002/cmdc.201500600
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Upregulation of the HGF and MSP growth-factor processing serine endopeptidases HGFA, matriptase and hepsin is correlated with increased metastasis in multiple tumor types driven by c-MET or RON kinase signaling. We rationally designed P1' -ketobenzothiazole mechanism-based inhibitors of these proteases. Structure-activity studies are presented, which resulted in the identification of potent inhibitors with differential selectivity. The tetrapeptide inhibitors span the P1-P1' substrate cleavage site via a P1' amide linker off the benzothiazole, occupying the S3' pocket. Optimized inhibitors display sub-nanomolar enzyme inhibition against one, two, or all three of HGFA, matriptase, and hepsin. Several compounds also have good selectivity against the related trypsin-like proteases, thrombin and FactorXa. Finally, we show that inhibitors block the fibroblast (HGF)-mediated migration of invasive DU145 prostate cancer cells. In addition to prostate cancer, breast, colon, lung, pancreas, gliomas, and multiple myeloma tumors all depend on HGF and MSP for tumor survival and progression. Therefore, these unique inhibitors have potential as new therapeutics for a diverse set of tumor types.
引用
收藏
页码:585 / 599
页数:15
相关论文
共 61 条
[41]   Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA [J].
Owen, Kate A. ;
Qiu, Deyi ;
Alves, Juliano ;
Schumacher, Andrew M. ;
Kilpatrick, Lynette M. ;
Li, Jun ;
Harris, Jennifer L. ;
Ellis, Vincent .
BIOCHEMICAL JOURNAL, 2010, 426 :219-228
[42]   The hepatocyte growth factor regulatory factors in human breast cancer [J].
Parr, C ;
Watkins, G ;
Mansel, RE ;
Jiang, WG .
CLINICAL CANCER RESEARCH, 2004, 10 (01) :202-211
[43]   SPINT2 Deregulation in Prostate Carcinoma [J].
Pereira, Marcia Santos ;
de Almeida, Gisele Caravina ;
Pinto, Filipe ;
Viana-Pereira, Marta ;
Reis, Rui Manuel .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2016, 64 (01) :32-41
[44]   A Reverse Binding Motif That Contributes to Specific Protease Inhibition by Antibodies [J].
Schneider, Eric L. ;
Lee, Melody S. ;
Baharuddin, Aida ;
Goetz, David H. ;
Farady, Christopher J. ;
Ward, Mick ;
Wang, Cheng-I ;
Craik, Charles S. .
JOURNAL OF MOLECULAR BIOLOGY, 2012, 415 (04) :699-715
[45]   c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers [J].
Shen, Aijun ;
Wang, Lu ;
Huang, Min ;
Sun, Jingya ;
Chen, Yi ;
Shen, Yan-Yan ;
Yang, Xinying ;
Wang, Xin ;
Ding, Jian ;
Geng, Meiyu .
CANCER RESEARCH, 2015, 75 (21) :4548-4559
[46]   Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors [J].
Smyth, Elizabeth C. ;
Sclafani, Francesco ;
Cunningham, David .
ONCOTARGETS AND THERAPY, 2014, 7 :1001-1014
[47]   Secondary amides of sulfonylated 3-amidinophenylalanine.: New potent and selective inhibitors of matriptase [J].
Steinmetzer, Torsten ;
Schweinitz, Andrea ;
Stuerzebecher, Anne ;
Doennecke, Daniel ;
Uhland, Kerstin ;
Schuster, Oliver ;
Steinmetzer, Peter ;
Mueller, Friedemann ;
Friedrich, Rainer ;
Than, Manuel E. ;
Bode, Wolfram ;
Stuerzbecher, Joerg .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (14) :4116-4126
[48]   Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation [J].
Suda, Kenichi ;
Tomizawa, Kenji ;
Osada, Hirotaka ;
Maehara, Yoshihiko ;
Yatabe, Yasushi ;
Sekido, Yoshitaka ;
Mitsudomi, Tetsuya .
LUNG CANCER, 2012, 76 (03) :292-299
[49]   Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression [J].
Sugie, Satoru ;
Mukai, Shoichiro ;
Yamasaki, Koji ;
Kamibeppu, Toyoharu ;
Tsukino, Hiromasa ;
Kamoto, Toshiyuki .
HUMAN CELL, 2016, 29 (01) :22-29
[50]   Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils [J].
Torti, Davide ;
Trusolino, Livio .
EMBO MOLECULAR MEDICINE, 2011, 3 (11) :623-636